170 related articles for article (PubMed ID: 26420767)
1. The importance of tissue handling of surgically removed breast cancer for an accurate assessment of the Ki-67 index.
Arima N; Nishimura R; Osako T; Nishiyama Y; Fujisue M; Okumura Y; Nakano M; Tashima R; Toyozumi Y
J Clin Pathol; 2016 Mar; 69(3):255-9. PubMed ID: 26420767
[TBL] [Abstract][Full Text] [Related]
2. Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues.
Neumeister VM; Anagnostou V; Siddiqui S; England AM; Zarrella ER; Vassilakopoulou M; Parisi F; Kluger Y; Hicks DG; Rimm DL
J Natl Cancer Inst; 2012 Dec; 104(23):1815-24. PubMed ID: 23090068
[TBL] [Abstract][Full Text] [Related]
3. Brief fixation enables same-day breast cancer diagnosis with reliable assessment of hormone receptors, E-cadherin and HER2/Neu.
Halilovic A; Bulte J; Jacobs Y; Braam H; van Cleef P; Schlooz-Vries M; Werner A; Boelens O; Nagtegaal I; de Wilt H; Bult P
J Clin Pathol; 2017 Sep; 70(9):781-786. PubMed ID: 28325747
[TBL] [Abstract][Full Text] [Related]
4. Immunostaining of estrogen receptor, progesterone receptor, MIB1 antigen, and c-erbB-2 oncoprotein in cytologic specimens: a simplified method with formalin fixation.
Suthipintawong C; Leong AS; Chan KW; Vinyuvat S
Diagn Cytopathol; 1997 Aug; 17(2):127-33. PubMed ID: 9258620
[TBL] [Abstract][Full Text] [Related]
5. Modulatory effect of neoadjuvant chemotherapy on the prognosis of patients with breast cancer.
Trifunovic J; Memisevic N; Nikolin B; Salma S; Dugandzija T; Vidovic V
J BUON; 2017; 22(2):638-643. PubMed ID: 28730768
[TBL] [Abstract][Full Text] [Related]
6. The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma.
Yildiz-Aktas IZ; Dabbs DJ; Bhargava R
Mod Pathol; 2012 Aug; 25(8):1098-105. PubMed ID: 22460807
[TBL] [Abstract][Full Text] [Related]
7. Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimens.
Tendl-Schulz KA; Rössler F; Wimmer P; Heber UM; Mittlböck M; Kozakowski N; Pinker K; Bartsch R; Dubsky P; Fitzal F; Filipits M; Eckel FC; Langthaler EM; Steger G; Gnant M; Singer CF; Helbich TH; Bago-Horvath Z
Virchows Arch; 2020 Oct; 477(4):545-555. PubMed ID: 32383007
[TBL] [Abstract][Full Text] [Related]
8. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.
von Minckwitz G; Sinn HP; Raab G; Loibl S; Blohmer JU; Eidtmann H; Hilfrich J; Merkle E; Jackisch C; Costa SD; Caputo A; Kaufmann M;
Breast Cancer Res; 2008; 10(2):R30. PubMed ID: 18380893
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical detection of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 in formalin-fixed breast carcinoma cell block preparations: correlation of results to corresponding tissue block (needle core and excision) samples.
Kinsella MD; Birdsong GG; Siddiqui MT; Cohen C; Hanley KZ
Diagn Cytopathol; 2013 Mar; 41(3):192-8. PubMed ID: 22611048
[TBL] [Abstract][Full Text] [Related]
10. Effect of fixation time on breast biomarker expression: a controlled study using cell line-derived xenografted (CDX) tumours.
Kao KR; Hasan T; Baptista A; Truong T; Gai L; Smith AC; Li S; Gonzales P; Voisey K; Eriwvo P; Power J; Denic N
J Clin Pathol; 2017 Oct; 70(10):832-837. PubMed ID: 28341657
[TBL] [Abstract][Full Text] [Related]
11. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma.
Goldstein NS; Ferkowicz M; Odish E; Mani A; Hastah F
Am J Clin Pathol; 2003 Jul; 120(1):86-92. PubMed ID: 12866377
[TBL] [Abstract][Full Text] [Related]
12. Short-Duration Rapid Chilling of Mastectomy Specimens Does Not Interfere With Breast Cancer Biomarker and Molecular Testing.
Kumarapeli AR; Bellamy W; Olgaard E; Massoll N; Korourian S
Arch Pathol Lab Med; 2019 Jan; 143(1):92-98. PubMed ID: 29932859
[TBL] [Abstract][Full Text] [Related]
13. Change in estrogen receptor, HER2, and Ki-67 status between primary breast cancer and ipsilateral breast cancer tumor recurrence.
Okumura Y; Nishimura R; Nakatsukasa K; Yoshida A; Masuda N; Tanabe M; Shien T; Tanaka S; Arima N; Komoike Y; Taguchi T; Iwase T; Inaji H; Ishitobi M;
Eur J Surg Oncol; 2015 Apr; 41(4):548-52. PubMed ID: 25682910
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemistry on old archival paraffin blocks: is there an expiry date?
Grillo F; Bruzzone M; Pigozzi S; Prosapio S; Migliora P; Fiocca R; Mastracci L
J Clin Pathol; 2017 Nov; 70(11):988-993. PubMed ID: 28596153
[TBL] [Abstract][Full Text] [Related]
15. Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant.
Robertson S; Rönnlund C; de Boniface J; Hartman J
Breast Cancer Res Treat; 2019 Apr; 174(3):795-805. PubMed ID: 30659433
[TBL] [Abstract][Full Text] [Related]
16. Impact of host and histopathological factors on the discrepancies in estrogen receptor, and progesterone receptor, and HER2 status between core needle biopsy and surgically excised tumors.
Nakamura R; Yamamoto N; Shiina N; Miyaki T; Ikebe D; Itami M; Shida T; Miyazaki M
Breast; 2016 Apr; 26():141-7. PubMed ID: 26732051
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
[TBL] [Abstract][Full Text] [Related]
18. The effects of under 6 hours of formalin fixation on hormone receptor and HER2 expression in invasive breast cancer: a systematic review.
Kalkman S; Barentsz MW; van Diest PJ
Am J Clin Pathol; 2014 Jul; 142(1):16-22. PubMed ID: 24926080
[TBL] [Abstract][Full Text] [Related]
19. Concordance of the molecular subtype classification between core needle biopsy and surgical specimen in primary breast cancer.
Pölcher M; Braun M; Tischitz M; Hamann M; Szeterlak N; Kriegmair A; Brambs C; Becker C; Stoetzer O
Arch Gynecol Obstet; 2021 Sep; 304(3):783-790. PubMed ID: 33585986
[TBL] [Abstract][Full Text] [Related]
20. Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer.
Pinhel IF; Macneill FA; Hills MJ; Salter J; Detre S; A'hern R; Nerurkar A; Osin P; Smith IE; Dowsett M
Breast Cancer Res; 2010; 12(5):R76. PubMed ID: 20920193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
